…China has won price cuts of more than 50 percent in national-level bargaining with drug companies on about five kinds of costly imported drugs…
That’s why I like ABT’s business model. In emerging markets, ABT doesn’t sell expensive patented drugs, but rather high-quality branded generics that many consumers prefer to locally made drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.